ProShare Advisors’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

ProShare Advisors’s Portfolio PAND Stock Details PAND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,437	Closed	-$447K	–	2459
2021 Q1	$447K	Buy	+7,437	New	+$269K	﹤0.01%	1520

ProShare Advisors's PAND Position: Q2 2021 in Review

ProShare Advisors sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 7,437 shares — an estimated $447K sold.

ProShare Advisors first reported a position in PAND in Q1 2021 and held it in 1 quarter. The position peaked at $447K in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

ProShare Advisors reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
ProShare Advisors sold 7,437 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $447K.
ProShare Advisors first reported a position in Pandion Therapeutics Inc. Common Stock in Q1 2021 and held it in 1 quarter.
ProShare Advisors's Pandion Therapeutics Inc. Common Stock position peaked at $447K in Q1 2021.
0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on ProShare Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.